• Gabather reported no net sales for Q2, while operating loss narrowed 22.58% to SEK 1.04 million.
• First-half operating loss widened 44.62% to SEK 2.38 million.
• Q2 net loss improved 21.40% to SEK 1.07 million.
• Cash and cash equivalents rose to SEK 3.69 million from SEK 3.14 million at end-2025.
• Started the TOTEMS patient study of GT-002 in schizophrenia spectrum; management said patient recruitment has not yet yielded enrolled patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gabather AB published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.